bpc-157 news 2025 october 🧬 Big in the peptide world. The FDA has scheduled a formal hearing in July to review 7 peptides — including and TB-500 — for legal compounding. This isn't approval A Federal Advisory Panel Just

In the CY 2025 PFS proposed rule (89 FR 62087 and 62088), we proposed the new cost measure exclusion policy to provide greater flexibilities to be responsive to any errors or significant changes outside of the control of MIPS eligible clinicians that negatively impact the ability of specific cost measure(s) to assess clinician performance

Reference: Neelakantan H, Vance V, Wetzel MD, Wang HY, McHardy SF, Finnerty CC, Hommel JD, Watowich SJ (2018)

Clinical Studies 14.1 Treatment of Postmenopausal Osteoporosis Study 1: The efficacy and safety of Reclast in the treatment of postmenopausal osteoporosis was demonstrated in Study 1, a randomized, double-blind, placebo-controlled, multinational study of 7736 women aged 65 to 89 years (mean age of 73) with either: a femoral neck BMD T-score less than or equal to -1.5 and at least two mild or one moderate existing vertebral fracture(s)

Differences in frequency or activity of effector cells may also contribute to differences in outcome